Thanks to #UEG for the invitation to participate in the promo for our new exciting event UEGW 2020 Virtual! 🙌#UEGEdu @myUEG It´s going to be amazing! Tagging @RuiCastroHD @siaq82 See you soon! 🧙‍♂️

Kono-S in Crohn's ileocaecal resection (n=70, FMC & IBD SA), now in early access in Techniques in Coloproctology. Shorter stay and fewer ileostomies, but mostly explained by patient selection. Biologics, not technique, predicted 12-mo recurrence. Great work leading this @warren_seow doi.org/10.1007/s10151-026-0…

🧪 Perianal fistulas clear infliximab faster 📍 ATLANTIC: prospective PK cohort, 148 patients on standard IV infliximab 5 mg/kg (62 perianal fistulizing CD vs 86 luminal CD) 📈 +23% clearance in progressive perianal disease (TOpClass ≥2c) during induction 🎯 Week 14: only 9% of PFCD patients reached their target trough (≥10 µg/mL) vs 46% of luminal CD (≥5 µg/mL) 🩸 Median trough at week 14: 2.9 vs 4.8 µg/mL 💡 Authors' case: front-loaded induction plus early TDM in PFCD ⚠️ Single centre, PK study, different targets per phenotype. No RCT yet of intensified vs standard induction 👇 Key numbers in one image 🔗 doi.org/10.1093/ecco-jcc/jja… #MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #PerianalCrohns

BEST OF @UegWeek in IBD 2026 BARCELONA Wed Nov 25 6 pm Norway/Spain 12 PM ET USA Register🔗shorturl.at/xpybm Speakers: Marie Truyens (Belgium) @GianlucaPellino (Spain) Mohammad Malik (Kuwait) Moderators: Heba Al-Farhan (Kuwait);@ign76 (Norway) See you!

📝 #GUTBlog | Could screening help pave the way for Crohn’s disease prevention? Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials. 📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials" 📝 Read the #GUTBlog: bit.ly/3UkCNxM 🔗 Read the paper in Gut: bit.ly/4zLZWYY #CrohnsDisease #IBD #FaecalCalprotectin #PreventionResearch

🔍 Can MRE predict surgery in pediatric Crohn's disease? New #JPGN study: 📏 Bowel wall thickness at diagnosis predicted surgery and anti-TNF escalation ⚠️ A threshold of >8 mm identified higher surgical risk doi.org/10.1002/jpn3.70407?u… #openaccess #PedsGI #IBD

For readers interested in CAR-T cell therapies for autoimmune diseases, here's a Review on the promise and pitfalls nature.com/articles/s41573-0… rdcu.be/47FDbGDbA9Na

⏲️Starting now: We are honored to welcome Prof. Saurabh Mehandru, MD, to the virtual Global IBD visiting professorship series @ClevelandClinic cmrccf.webex.com.mcas.ms/wbx… @IBD_FloMD @SaraElOualiMD @EmadMansoorMD @ManuelBragaMD @IBDBen @KatieFalloonMD @SWexner @CharlieMuz @JessPhilpottMD @MRegueiroMD @BenClement_MD @ibdtweets @IBDimmunology @MaiaKayalMD @MountSinaiGI @JeanFredericCo1

❇️ Big pleasure to share about @YOGI_IBD at @my_ueg #UEGW26

STRIDE-III makes an important distinction: not every IBD target should trigger the same clinical action. Some guide treatment change, others refine monitoring, and patient-centred outcomes remain part of treat-to-target care. #IBD #CrohnsDisease #UlcerativeColitis #TreatToTarget #Gastroenterology #ClinicalGuidelines #GastroAGI

First thoughts on VERDICT ... pending publication of the full manuscript by @vipuljairath and colleagues. 672 pts with mod-sev UC randomised to 1 of 3 targets on a vedo-based algorithm (stepped up to q4w if needed), with central reading of endoscopy and histology: • G1: symptoms • G2: + endoscopic remission (MES 0–1) • G3: + histological remission (Geboes <2B.0) The primary outcome was time to a UC complication over up to 80 weeks from reaching the target. Mean age was 41, with eight years of disease, a Mayo score of 8.7, nearly two-thirds Mayo 3, almost half on steroids and a fifth after an advanced therapy. By week 48, 74% (G1), 56% (G2) and 52% (G3) had reached their targets. Treating to endoscopy made a huge difference: 22% of G1 had a UC complication, against 7% in G2 and 9% in G3. The primary comparison, histology (G3) against symptoms (G1), gave a hazard ratio of 0.33 (95% CI 0.17 to 0.67), and endoscopy against symptoms (G2 vs G1) gave 0.30 (0.14 to 0.64). In the Q&A, Vip said the effect was greater still at Mayo 0 (data not shown). About half the complications were rescue therapy for a flare; only one was an admission and none a colectomy. We don't know what happened to the patients who did not meet their targets, across all groups. But there was no clear additive benefit from histology: G3 vs G2 had a HR of 1.10 (0.45 to 2.69). Read that with one more number. 79% of group 2 (99 of 125) were also in histological remission when they reached their endoscopic target, so the groups were clinically similar and the comparison rested on about one in five. And endoscopy was read centrally. When it is, Mayo 0 is usually free of neutrophils: 84% in LUCENT and over 90% in QUASAR. Local reading is another matter. In OCTAVE, central readers confirmed only 38 to 46% of local Mayo 0 calls. We do not have the equivalent data on paired centrally read endoscopy plus histology in UC patients not on advanced therapy (as far as I know) - that might matter in the real world. We know histological inflammation carries long-term risk, including cancer. VERDICT covers only one to two years. Most of that long-term evidence comes from scoring old H&E slides, recut from paraffin blocks if needed. You can't go back and re-read an old endoscopy the same way. So ... with endoscopy read well, histology added nothing we could detect. In the clinic, where we read our own scopes, it may still catch what endoscopy misses. FINALLY ... in the debate on histology vs endoscopy we must not lose sight of just how important VERDICT is for treat-to-target in UC. It is very clear that treating to endoscopic healing makes a huge difference to important patient outcomes. Of course, I still want to know if calprotectin is a good enough proxy for the real world ... ok let's await the full paper!

🌎 Our multinational IBD study in northern Central America found UC predominated, with delayed diagnosis and limited access to testing and advanced therapies. 📖Published in @IBDjournals 🔗 tinyurl.com/IBDC4 Thanks to my coauthors and mentors, @DebProctorMD and @AlexLevyMD @YaleDigestive

Heading home after my first #UEGWeek at Barcelona. Getting updated. Lots of contemplation. New ideas. Motivation. But most of all, meeting friends and mentors from around the world. Thank you @my_ueg ! Now leaving Barcelona with wonderful memories :)

Diet can enhance the efficacy of biologics It’s time to integrate diet AND drugs for better outcomes in patients with CD compared to biologics alone, according to @BonehRotem #UEGWeek2026 @my_ueg

🎈

Latam- Igondomar meeting at #uegweek2026 @ign76 @pancco_org @SebastianFerr18

Welcome if you are around @YOGI_IBD !!!

Stride III presented by @DignassAxel at #UEGW26 👇🏻

Prof Florian Rieder: (OP-003) PALI-2108 (PDE4 inhibitor) for fibrostenosing Crohn’s was safe and possibly effective (n=5) with favorable PK and target engagement #uegweek2026

Honored to chair the afternoon session with my dear friend @SSiakavellas @my_ueg #UEGW2026

❇️ See you later today for a new "Mistakes in Lower GI" session at @UegWeek 26 Barcelona Practical approaches to Newly disgnosed Crohn´s patients and Ostomy management. Join the conversation! Welcome! 🖐️